The dry eye disease market was valued at USD 7.39 Billion in 2025 driven by the development of innovative treatment options across the 8 major markets. It is expected to grow at a CAGR of 6.50% during the forecast period of 2026-2035 and attain a market value of USD 13.87 Billion by 2035. The market is driven by factors like aging populations, environmental influences (e.g., air pollution and screen time), and advances in diagnostic technologies and treatments, driving demand for effective management solutions.
Base Year
Historical Period
Forecast Period
The growing aging population is expected to drive the demand for dry eye disease treatments as age-related conditions increase.
Rising screen time and environmental factors are leading to higher incidences of dry eye disease, boosting market growth.
Advances in non-invasive diagnostic tools and therapies will enhance treatment efficacy, contributing to the market's expansion.
Compound Annual Growth Rate
6.5%
Value in USD Billion
2026-2035
*this image is indicative*
Dry eye disease is a common condition where the eyes do not produce enough tears or produce poor-quality tears, leading to irritation, redness, and a gritty sensation. It can result from aging, environmental factors, screen overuse, or underlying health issues. Symptoms often worsen in dry or windy conditions. If left untreated, it can affect vision and quality of life, but it is manageable with appropriate care and treatments. The market is expected to grow at a CAGR of 6.50% during the forecast period of 2026-2035.
AI Integration and Clinical Study Partnerships to Boost Market Growth
The rising demand for AI integration in ophthalmology and the increasing focus on improving clinical data workflows are driving advancements in the dry eye disease (DED) market. For instance, in September 2024, RetinAI U.S. Inc. partnered with MAXO, a reading centre affiliated with TFS HealthScience, to support two critical DED clinical trials. These studies will utilize the AI-powered RetinAI Discovery® platform to optimize imaging analysis, real-time data sharing, and global collaboration. This development is expected to accelerate clinical research efficiency and fuel market growth during the forecast period.
Patient-Centric Research Enhancing Awareness and Dry Eye Disease Market Development
The growing focus on patient-centred care and quality-of-life evaluations in eye health are crucial market drivers. For instance, in February 2025, a study by Italian researchers used a narrative medicine approach to explore patient and caregiver experiences in dry eye disease. Involving 171 patients, 37 caregivers, and 81 ophthalmologists, the research offered qualitative insights into DED severity and emotional impact. This approach is anticipated to enhance understanding of patient needs, guide therapeutic strategies, and encourage innovation, thereby supporting dry eye disease market development in the coming years.
Some of the notable trends include rising product launches, adoption of novel delivery technologies, and changes in the regulatory support.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Dosage Form
Market Breakup by Sales Channel
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Eye Drops and Solutions to Lead the Market Share by Dosage Form
Eye drops and solutions dominate the dry eye disease market due to their immediate relief, easy administration, and widespread availability. These formulations effectively hydrate and lubricate the eyes, making them the preferred choice for both over-the-counter and prescription use. Their ability to address various severity levels of dry eye symptoms positions them as the leading dosage form, driving market growth during the forecast period.
The United States is poised to lead the market due to high disease prevalence, a growing aging population, and robust healthcare infrastructure. Increasing awareness, frequent screen exposure, and strong adoption of advanced therapies further support market dominance. Additionally, the presence of leading pharmaceutical players and substantial investments in R&D continue to drive innovation and fuel regional market growth throughout the forecast period.
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Novartis is a key player in the dry eye In June 2022, Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a preservative-free, electromechanical ocular delivery platform enabling precise dosing of ophthalmic drugs. This strategic move enhances Novartis’s capabilities in dry eye disease treatment by improving drug delivery efficiency, positioning the company as a key innovator in ophthalmic care and contributing to the market’s technological advancement and growth.
AbbVie, In., is a global healthcare company with a significant presence in the market. In April 2025, AbbVie submitted a Biologics License Application to the FDA for trenibotulinumtoxinE (TrenibotE), aiming to expand its aesthetics portfolio. While primarily for glabellar lines, AbbVie’s growing biologics expertise and robust regulatory progress also reinforce its ophthalmic R&D focus, potentially benefitting adjacent segments like dry eye disease and supporting the company’s role in the broader eyecare market.
Sun Pharmaceutical Industries Ltd. specializes in products and services for ophthalmology care. In November 2024, Sun Pharmaceutical Industries Ltd. presented compelling Phase 4 data at ESCRS 2024 showing cyclosporine ophthalmic solution 0.09% (Cequa) significantly improved dry eye disease symptoms over 12 weeks in patients unresponsive to Restasis. This reinforces Sun Pharma’s leadership in DED therapy and highlights the potential for improved treatment outcomes, bolstering market confidence and therapeutic innovation.
Santen Pharmaceutical is a global leader, offering a broad portfolio of products across multiple therapeutic areas. In July 2023, Harrow announced agreements with affiliates of Santen Pharmaceutical Co., Ltd. to acquire U.S. and Canadian commercial rights to select branded eyecare products. This move strengthens Santen’s strategic collaborations and market positioning while enhancing Harrow’s portfolio in dry eye and related indications, ultimately supporting regional market expansion and accessibility in North America.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical (subsidiary of Otsuka Holdings Co., Ltd.), OASIS Medical, Viatris Inc, and Bausch Health Companies, Inc., among others.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Dosage Form |
|
| Breakup by Sales Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share